Cost element | Resource use: number and unit description (where relevant) | Unit cost (CHF) | Sources |
---|---|---|---|
VN treatment | |||
Acquisition cost (public price) of VN | 1 | 759'968 | Novartis |
Cost of retinal surgery | 2 administrations (1 per eye) | 3474 | |
Cost of prednisone | Regimen cost for both eyes | 86 | |
Cost of control visits with optical coherence tomography | 4 | 271 | |
Adverse events | |||
Cataract | Once in 15% of VN patients | 4’869 | |
Eye inflammation | Once in 10% of VN patients | 52 | |
Elevated intraocular pressure | Once in 20% of VN patients | 220 | |
Testing prior to VN treatment | |||
Testing for viable retinal cells | All IRD patients with RPE65 mutation are tested. It is estimated by medical examiners in Study 301/302, that 55% have sufficient viable cells and 45% do not | 271 / 0.55 = 493 | |
Costs of visual impairment | |||
Excess hospitalisations in HS2-5 patients aged 65+ years | Compared to HS1 patients aged 65+ years, 0.2 additional hospitalisations per year | 12’543 per hospitalisation | |
Technical assistance (including vision aids) | Relative levels of resource use estimated at 1.00 for all HS1 patients, 0.96 for HS2-5 patients aged 18-64 years, and 1.34 for HS2-5 patients aged 65+ years | 2’133 per year | |
Community care (Spitex) | 6% of HS2-5 patients aged 65+ years | 7’063 per year | |
Residential care | 30% of HS2-5 patients aged 65+ years | 64’537 per year | |
Societal costs (scenario analysis) | |||
Excess education costs of HS2-5 patients aged below 18 years | All relevant patients | 21’094 per year | |
Productivity loss of HS2-5 patients aged 18-64 years | 80% reduction to average worker’s annual salary of CHF 42,843 | 42’843 per year | |
Productivity loss of family caregivers of patients aged 65+ years | Annually, 144 hours for HS1 patients, 676 hours for HS2 patients, 1608 hours for HS3-5 patients; conservatively accounted for only 25% of caregiving hours for all patients. | 43 per hour |